Skip to main content

inclisiran (Leqvio®)

 

Appraisal in progress

Indication

Status: In progress

In adults with primary hypercholesterolaemia (heterozygous familial and non‑familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid‑lowering therapies in patients unable to reach LDL‑C goals with the maximum tolerated dose of a statin, or; alone or in combination with other lipid‑lowering therapies in patients who are statin‑intolerant, or for whom a statin is contraindicated.

Medicine details

Medicine name inclisiran (Leqvio®)
Formulation 284 mg solution for injection
Reference number 3746
Indication

As above

Company Novartis Pharmaceuticals UK Ltd
BNF chapter Cardiovascular system
Submission type Full
Status In progress
NMG meeting date 05/01/2022
AWMSG meeting date 09/02/2022
Date of issue TBC